Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia
Conditions
Brief summary
This pilot clinical trial studies infusion of expanded cord blood hematopoietic progenitor cells following combination chemotherapy in treating younger patients with acute myeloid leukemia that has relapsed or has not responded to treatment. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Chemotherapy also kills healthy infection-fighting cells, increasing the risk of infection. The infusion of expanded cord blood hematopoietic progenitor cells may be able to replace blood-forming cells that were destroyed by chemotherapy. This cellular therapy may decrease the risk of infection following chemotherapy.
Interventions
Given IV
DRUGCytarabine
Given IV
DRUGFilgrastim
Given SC or IV
DRUGFludarabine Phosphate
Given IV
Sponsors
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
Nohla Therapeutics, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Months to 30 Years
Healthy volunteers
No
Inclusion criteria
* Patients must have a diagnosis of AML or acute leukemia of ambiguous lineage according to World Health Organization (WHO) classification with \>= 5% of disease in bone marrow (BM) * Recipients of prior allogeneic hematopoietic stem cell transplantation for AML or acute leukemia of ambiguous lineage are eligible if they do not have graft-versus-host disease (GVHD) or they have quiescent GVHD whether or not they are receiving immunosuppressive therapy * Must have a Lansky or Karnofsky performance status of \>= 50; use Karnofsky for patients \> 16 years of age and Lansky for patients =\< 16 years of age * Patients must have recovered from the acute toxicity of all prior chemotherapy * The following amounts of time must have elapsed prior to entry on study: * 2 weeks from local radiation therapy (XRT) * 8 weeks from prior craniospinal or if \> 50% of the pelvis has been irradiated * 6 weeks must have elapsed if other bone marrow radiation has occurred * Adequate cardiac, renal, pulmonary, and hepatic function * Patient must have a life expectancy of at least 2 months * Females of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment * Females of childbearing potential and males should agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation
Exclusion criteria
* Recipients of prior allogeneic hematopoietic stem cell transplant (HSCT) with active acute or chronic GVHD * Patients with history of Down's syndrome, Fanconi anemia or other known marrow failure condition * Patients currently receiving other investigational drugs are not eligible * Current concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol with the exception of intrathecal chemotherapy; this includes the tyrosine kinase inhibitor sorafenib which must not be initiated until patient demonstrates count recovery * Patients with a systemic fungal, bacterial, viral, or other infection not controlled despite appropriate antibiotics or other treatment; uncontrolled systemic infections require infectious disease consultation for verification * Patients who are platelet refractory prior to initiation of protocol therapy * Pregnant or lactating patients * Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of NCI CTCAE grade > 3 infusional toxicities | Up to 2 years | — |
| Occurrence of transfusion associated graft versus host disease | Up to 2 years | — |
| Incidence of platelet refractoriness in the presence of alloimmunization as a direct result of ex vivo expanded cord blood product infusion | Up to 2 years | — |
| Incidence of delayed marrow recovery | Up to day 42 | Failure to achieve ANC \>= 500 cells/µl by day 42 post treatment with marrow cellularity \< 5% and marrow blast count \< 5%. |
| Rate of treatment related mortality | Up to 2 years | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of complete remission | Up to 2 years | — |
| Time to neutrophil recovery | Up to 2 years | ANC \>= 100 cells/ul and 500 cells/ul |
| Overall survival | Up to 2 years | — |
| Leukemia-free survival | Up to 2 years | — |
| In vivo persistence of ex vivo expanded cellular therapy | Up to 2 years | Assessed by peripheral blood cell sorted deoxyribonucleic acid (DNA) chimerisms of the cluster of differentiation myeloid and lymphoid cell lineages as well as whole marrow chimerisms. |
| Patient and infused expanded cord blood cells immune interaction | Up to 2 years | Assessed by performing host-donor studies. |
| Incidence of NCI CTCAE grade 3 or 4 infections | First 30 days following FLAG administration | — |
| Incidence of NCI CTCAE grade > 3 chemotherapy-related toxicity in the first 30 days following fludarabine phosphate, cytarabine, and filgrastim (FLAG) therapy | First 30 days following FLAG administration | — |
Countries
United States
Outcome results
None listed